MCID: ISC004
MIFTS: 58

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases

Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 54 43 15 17 71
Acute Coronary Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:326
MeSH 43 D007511
NCIt 49 C34738
SNOMED-CT 67 52674009
UMLS 71 C0022116 C0948089

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to retinal ischemia and limb ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000275929 (), and among its related pathways/superpathways are Pathways in cancer and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Paclitaxel and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and liver, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1546)
# Related Disease Score Top Affiliating Genes
1 retinal ischemia 35.0 VEGFA HMOX1 CXCL12
2 limb ischemia 35.0 VEGFA CXCL12 ACE
3 vascular disease 33.7 VEGFA PON1 HMOX1 EPO CXCL12 ACE
4 lipoprotein quantitative trait locus 33.6 VEGFA PON1 GJA1 ACE
5 microvascular complications of diabetes 5 33.2 VEGFA SOD2 PON1 CXCL12 ACE
6 ischemic colitis 33.2 VEGFA HMOX1 ACE
7 myocardial infarction 33.1 VEGFA PON1 HMOX1 GJA1 EPO CXCL12
8 coronary stenosis 32.1 PON1 CXCL12 ACE
9 peripheral artery disease 31.9 VEGFA HMOX1 ACE
10 end stage renal disease 31.8 VEGFA SOD2 PON1 EPO ACE
11 arteriosclerosis 31.7 PON1 HMOX1 CXCL12 ACE
12 pulmonary edema 31.7 HMOX1 EPO ACE
13 atherosclerosis susceptibility 31.7 VEGFA PON1 HMOX1 ACE
14 stroke, ischemic 31.6 VEGFA SOD2 PON1 GJA1 CXCL12 CASP9
15 chronic kidney disease 31.6 VEGFA PON1 HMOX1 EPO ACE
16 peripheral vascular disease 31.5 VEGFA EPO ACE
17 heart disease 31.5 VEGFA SOD2 PON1 HMOX1 GJA1 EPO
18 retinal artery occlusion 31.4 VEGFA HMOX1 ACE
19 vascular dementia 31.3 VEGFA PON1 ACE
20 retinal vein occlusion 31.3 VEGFA CXCL12 ACE
21 diabetic neuropathy 31.3 VEGFA SOD2 PON1 EPO ACE
22 neuroblastoma 31.3 VEGFA SOD2 REST HMOX1 EGR1 CXCL12
23 sleep apnea 31.2 VEGFA EPO ACE
24 hypertension, essential 31.2 VEGFA SOD2 PON1 HMOX1 GJA1 EPO
25 deficiency anemia 31.2 PON1 HMOX1 EPO ACE
26 diabetic macular edema 31.1 VEGFA SOD2 EPO
27 uremia 31.0 PON1 EPO ACE
28 alzheimer disease 31.0 SOD2 REST PON1 MAP3K5 HMOX1 EGR1
29 dilated cardiomyopathy 30.8 VEGFA SOD2 HMOX1 GJA1 CASP9 ACE
30 hypertensive encephalopathy 30.5 VEGFA EPO ACE
31 body mass index quantitative trait locus 11 30.5 VEGFA SOD2 PRKAA2 PON1 HMOX1 ACE
32 migraine with aura 30.4 SOD2 CXCL12 ACE
33 hypertensive retinopathy 30.2 VEGFA ACE
34 severe nonproliferative diabetic retinopathy 30.0 VEGFA ACE
35 transient cerebral ischemia 12.7
36 chronic intestinal vascular insufficiency 11.8
37 hypoxia 11.6
38 cerebral hypoxia 11.6
39 nonarteritic anterior ischemic optic neuropathy 11.5
40 legg-calve-perthes disease 11.5
41 sturge-weber syndrome 11.5
42 arterial calcification, generalized, of infancy, 1 11.5
43 lateral medullary syndrome 11.5
44 aortic dissection 11.4
45 myocardial stunning 11.4
46 volkmann contracture 11.4
47 peritonitis 11.4
48 short bowel syndrome 11.4
49 respiratory failure 11.4
50 fibromuscular dysplasia 11.4

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


muscle weakness, polydipsia, angina pectoris, anoxemia

MGI Mouse Phenotypes related to Ischemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 ACE ADORA3 CASP9 CXCL12 EGR1 EPO
2 cellular MP:0005384 10.25 CASP9 CXCL12 EGR1 EPO GJA1 HMOX1
3 behavior/neurological MP:0005386 10.2 ACE ADORA3 EGR1 GJA1 HMOX1 HYOU1
4 homeostasis/metabolism MP:0005376 10.13 ACE ADORA3 EGR1 EPO GJA1 HMOX1
5 hematopoietic system MP:0005397 10.11 ACE ADORA3 CASP9 CXCL12 EGR1 EPO
6 immune system MP:0005387 10.03 ACE ADORA3 CASP9 CXCL12 EGR1 EPO
7 liver/biliary system MP:0005370 9.7 ACE CXCL12 EGR1 EPO HMOX1 SOD2
8 muscle MP:0005369 9.56 CXCL12 EPO GJA1 HMOX1 NOL3 PRKAA2
9 respiratory system MP:0005388 9.23 ADORA3 CASP9 EGR1 EPO GJA1 HMOX1

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 981)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
4
Zolpidem Approved Phase 4 82626-48-0 5732
5
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
6
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Capsaicin Approved Phase 4 404-86-4 1548943
9
Gliclazide Approved Phase 4 21187-98-4 3475
10
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
11
Nadroparin Approved, Investigational Phase 4
12
Streptokinase Approved, Investigational Phase 4 9002-01-1
13
Adenosine Approved, Investigational Phase 4 58-61-7 60961
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
16
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
19
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
20
Famotidine Approved Phase 4 76824-35-6 3325
21
Morphine Approved, Investigational Phase 4 57-27-2 5288826
22
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
23
Simvastatin Approved Phase 4 79902-63-9 54454
24
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
25
Fondaparinux Approved, Investigational Phase 4 104993-28-4
26
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
27
Pantoprazole Approved Phase 4 102625-70-7 4679
28
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
29
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
30
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
31
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
32
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
33
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
34
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
35
Insulin lispro Approved Phase 4 133107-64-9
36
Sodium citrate Approved, Investigational Phase 4 68-04-2
37
Saxagliptin Approved Phase 4 361442-04-8 11243969
38 Hydrotalcite Approved, Experimental, Investigational Phase 4 12304-65-3
39
Sucralfate Approved Phase 4 54182-58-0
40
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
41
Eplerenone Approved Phase 4 107724-20-9 150310 443872
42
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
43
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
44
Digoxin Approved Phase 4 20830-75-5 30322 2724385
45
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
46
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
47
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
48
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
49 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
50
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693

Interventional clinical trials:

(show top 50) (show all 7888)
# Name Status NCT ID Phase Drugs
1 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
2 APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation Unknown status NCT02789917 Phase 4
3 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome Unknown status NCT01245803 Phase 4 additional rosuvastatin loading;placebo control
4 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
5 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel
6 Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial. Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
7 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
8 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
9 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
10 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
11 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
12 Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) Unknown status NCT02592720 Phase 4 cocktail
13 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
14 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
15 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
16 Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome Unknown status NCT02809820 Phase 4 Carvedilol;Metoprolol
17 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
18 A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome Unknown status NCT03007524 Phase 4 High dose Rosuvastatin;Low dose Rosuvastatin
19 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
20 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
21 Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention Unknown status NCT01040936 Phase 4 Atorvastatin;Atorvastatin
22 Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
23 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
24 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
25 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
26 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
27 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
28 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
29 An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI(EARLY-MYO II) Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
30 A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS Unknown status NCT02284503 Phase 4 Rosuvastatin
31 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
32 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
33 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
34 Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome Unknown status NCT02379676 Phase 4 Ticagrelor;Clopidogrel
35 A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography Unknown status NCT02464397 Phase 4
36 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
37 Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial Unknown status NCT01690832 Phase 4 standard saline infusion;fenoldopam infusion
38 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
39 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
40 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
41 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
42 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ Unknown status NCT00914420 Phase 4
43 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
44 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
45 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
46 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
47 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
48 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
49 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
50 A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS. Unknown status NCT01918150 Phase 4

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

40
Heart, Brain, Liver, Endothelial, Kidney, Testes, Lung

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 52551)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 54 61
20235222 2010
2
Ischemia induces endoplasmic reticulum stress and cell apoptosis in human brain. 54 61
20347937 2010
3
Vascular responses to hypoxia and ischemia. 61 54
19729615 2010
4
Effects of AMP-activated protein kinase in cerebral ischemia. 54 61
20010958 2010
5
Loss of clusterin expression worsens renal ischemia-reperfusion injury. 54 61
20007348 2010
6
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. 54 61
20138968 2010
7
Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. 54 61
20152804 2010
8
Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. 54 61
20222175 2010
9
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 61 54
20133634 2010
10
A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. 61 54
19836457 2010
11
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 61 54
20190407 2010
12
Allopurinol, xanthine oxidase, and cardiac ischemia. 61 54
19794315 2009
13
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. 61 54
19850943 2009
14
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. 61 54
19920350 2009
15
Association of cystatin C with ischemia in patients with coronary heart disease. 61 54
19816865 2009
16
Low-density lipoproteins oxidized after intestinal ischemia/reperfusion in rats. 54 61
19482302 2009
17
Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. 54 61
19917352 2009
18
Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. 54 61
19682205 2009
19
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 61 54
19622751 2009
20
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 54 61
19576596 2009
21
Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. 61 54
19753114 2009
22
Lentiviral-mediated overexpression of Bcl-xL protects primary endothelial cells from ischemia/reperfusion injury-induced apoptosis. 54 61
19716047 2009
23
Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. 61 54
19344900 2009
24
Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. 61 54
19498441 2009
25
N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. 61 54
19685518 2009
26
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 61 54
19596001 2009
27
Increased expression of monocarboxylate transporter 1 after acute ischemia of isolated, perfused mouse hearts. 54 61
19604494 2009
28
Adrenomedullin ameliorates ischemia reperfusion injury in rat livers. 54 61
19663270 2009
29
Use of changes in B-type natriuretic peptides to detect ischemia in selected patients. 61 54
18632168 2009
30
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 61 54
19443639 2009
31
Ischemia/reperfusion Lung Injury Increases Serum Ferritin and Heme Oxygenase-1 in Rats. 61 54
19885035 2009
32
Dietary sources of nitrite as a modulator of ischemia/reperfusion injury. 61 54
19212422 2009
33
Angiopoietin-1 in the treatment of ischemia and sepsis. 54 61
18791498 2009
34
Circulating biochemical markers of brain damage in infants complicated by ischemia reperfusion injury. 54 61
19355873 2009
35
Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. 61 54
19456402 2009
36
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 54 61
19371824 2009
37
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 61 54
19279473 2009
38
[Biochemical markers in the diagnosis of acute coronary syndrome]. 61 54
19681456 2009
39
FAK regulates cardiomyocyte survival following ischemia/reperfusion. 61 54
19028502 2009
40
Regulation of cardiac afferent excitability in ischemia. 54 61
19655108 2009
41
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 61 54
18812468 2009
42
Ischemia alters the expression of connexins in the aged human brain. 61 54
19794823 2009
43
Ischemia-induced up-regulation of heme oxygenase-1 protects from apoptotic cell death and tissue necrosis. 61 54
18262556 2008
44
Pretreatment with bone morphogenetic protein-7 (BMP-7) mimics ischemia preconditioning following intestinal ischemia/reperfusion injury in the intestine and liver. 61 54
18461025 2008
45
Markers of acute coronary syndrome in emergency room. 61 54
18971915 2008
46
Increases in myeloperoxidase levels after exercise in myocardial perfusion scintigraphy are not induced by myocardial ischemia. 54 61
18601914 2008
47
Transient cerebral ischemia leads to TGF-beta2 expression in Golgi apparatus organelles. 61 54
18691075 2008
48
Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. 61 54
18559422 2008
49
Dopamine D1-like receptors depress excitatory synaptic transmissions in striatal neurons after transient forebrain ischemia. 54 61
18535281 2008
50
The role of erythropoietin as an inhibitor of tissue ischemia. 61 54
18566695 2008

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.49 VEGFA HMOX1 EPO CXCL12 CASP9
2 11.77 VEGFA REST GJA1 EGR1
3 11.62 VEGFA HMOX1 EPO
4 11.6 VEGFA PRKAA2 MAP3K5 HMOX1
5
Show member pathways
11.41 MAP3K5 CXCL12 CASP9
6 11.23 PRKAA2 MAP3K5 GJA1 CASP9
7 10.74 VEGFA HMOX1 EPO CXCL12

GO Terms for Ischemia

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 VEGFA PRKAA2 NOL3 HYOU1 EPO
2 negative regulation of gene expression GO:0010629 9.86 VEGFA REST PRKAA2 ACE
3 regulation of apoptotic process GO:0042981 9.83 NOL3 GJA1 EGR1 CASP9
4 negative regulation of cell proliferation GO:0008285 9.83 SOD2 REST HMOX1 GJA1 ADORA3
5 apoptotic process GO:0006915 9.8 NOL3 MAP3K5 HMOX1 GJA1 EPO CASP9
6 positive regulation of neuron differentiation GO:0045666 9.72 REST EPO CXCL12
7 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.63 VEGFA EPO EGR1
8 regulation of blood pressure GO:0008217 9.58 SOD2 HMOX1 ACE
9 induction of positive chemotaxis GO:0050930 9.54 VEGFA CXCL12
10 response to hypoxia GO:0001666 9.5 VEGFA REST NOL3 HMOX1 EPO EGR1
11 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.49 SOD2 NOL3
12 positive regulation of chemokine biosynthetic process GO:0045080 9.48 HMOX1 EGR1
13 positive regulation of axon extension involved in axon guidance GO:0048842 9.37 VEGFA CXCL12
14 response to ischemia GO:0002931 9.28 SLC8A2 REST NOL3 MAP3K5 HYOU1 GPR31
15 negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway GO:1903298 9.26 NOL3 HYOU1
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.16 VEGFA ACE

Sources for Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....